Pharma & Biotech

BioNTech SE is executing a remarkable strategic transformation, evolving from its pandemic-era identity into a diversified biotechnology powerhouse. This shift...

Essa Pharma Inc. has initiated the final phase of its corporate wind-down, completing the previously announced transaction with XenoTherapeutics, Inc....

A notable surge in institutional investment activity and revised analyst outlooks are driving significant momentum for Amicus Therapeutics. Recent regulatory...

Medical technology firm Haemonetics finds itself at the center of a curious market contradiction. The company recently posted quarterly results...

A superficial glance at Oramed's latest quarterly report suggests a company in good health, having posted a net profit. However,...

BridgeBio Pharma has captured significant attention following compelling long-term data presented at the European Society of Cardiology congress. The biopharmaceutical...

Ocugen has achieved a critical regulatory milestone after European Medicines Agency (EMA) officials endorsed the company's development strategy for its...

Despite reporting progress in its pivotal Phase 3 trial for a hepatitis C combination therapy, Atea Pharmaceuticals Inc. witnessed its...

Autolus Therapeutics presents investors with a compelling puzzle. The clinical-stage biopharmaceutical company boasts a recently approved cancer therapy and impressive...

PepGen Inc. finds itself navigating a perfect storm of declining investor confidence, legal challenges, and a strategic pipeline overhaul. The...